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When one mentions muscular dystrophy, the mental picture that emerges is that ofDuchene Muscular 
Dystrophy (DMD). In reality, the term muscular dystrophy refers to around six, heterogenous groups 
of inherited disorders characterised by progressive muscle wasting and weakness. The commonfeature 
of all the dystrophies is the histological picture of muscle biopsy with the typical signs of muscle fibre 
variation, muscle necrosis and increasedfat and connective tissues. 
Attempting to classify muscular dystrophy is not easy and 
straight forward but Walton and Nattrass in 1954 formulated a 
classification (further elaborated by Walton in 1964) that is based 
on two principles - mode of inheritance and the predominant 
affected muscle group (Figure 1). Though this classification is 
still in use today, the identification of molecular genetics defects 
underlying particular dystrophies have distorted this clinical 
classification, Due to editorial constraints, this article shall 
attempt to give an overview of the molecular pathologies 
underlying the major classes of muscular dystrophy. 
Clinically, the common feature of these disorders is muscle 
weakness, but the prognosis of the disorders shows great 
variability. 
Duchene-Type Muscular Dystrophy 
The commonest form of Muscular Dystrophy is the Duchenne-
type. It is inherited as an X linked recessive trait and therefore 
predominantly affects boys. It is characterised by progressive 
muscle wasting and weakness and usually results in inability to 
walk by age 12 and death in the 20's. Some degree of intellectual 
impairment might be present in up to a third of cases. A similar 
hllt diniC';jl1y mikff'f C'nnrlitinn, Bf'dwr-typp mll'Wlll;jr rly~trophy 
(BMD), has an onset in the teenage years or early 20's, with 
loss of ability to walk occurring much later and survival is 
beyond middle age. 
The gene was localized in 1982, discovered in 1987 with its 
protein product identified as dystrophin. The gene is the largest 
gene associated with a disease (2.4 million base pairs) contains 
85 exons with the introns making up 98% of the gene. Being a 
cytoskeletal protein located beneath the sarcolemma, dystrophin 
is localised at the periphery of muscle fibres. The discovery of 
the protein, helped in the definition of the pathophysiological 
difference between Duchenne-type and Becker-type dystrophies, 
with the former showing complete absence of the protein and the 
later showing a reduced presence. Dystrophin forms part of a 
complex of proteins called the Dystrophin-Glycoprotein Complex 
(DGC) - a complex of five classes of proteins (dystroglycans, 
syntrophins, dystrobrevins, sarcoglycans and sarcospan) assembled 
with either dystrophin or its autosomal homologue utrophin (Figure 
2). Utrophin is developmentally controlled i.e. it is highly expressed 
in muscle tissue during the foetal and neonatal period, but is 
sU}JJJressed and cunfmed ot the sarculermna after birth. This 
complex binds the cytoskeleton to the sarcolemma and is thought 
to help maintain the structure of muscle cells. 
The DGC proteins have also been found to be expressed in non-
muscle tissues especially in the brain and retina, and might explain 
the abnormalities present in these tissues in DMD patients. 
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Figure 1: Distribution of predominant muscle weakness in 
different types of dystrophy 
Facioscapulohumeral Muscular Dystrophy 
Facioscapulohumeral Muscular Dystrophy (FMD) is 
characterized by weakness of the facial, scapulohumeral, anterior 
tibial and pelvic girdle muscles with retinal vascular disease, 
sensOlY hearing loss arId in some cases, abnormalities of the 
central nervous system. The responsible gene is located on 
chromosome 4, and the condition is inherited as an autosomal 
dominant trait. Individuals suffering of the condition are usually 
mildly affected though some may later become dependent on 
wheelchairs. 
Almost all the patients with FSHD have been found to have 
a deletion within the D4Z4 rcpcat rcgion (chromosomc 4q35). 
However, studies have failed to identify a gene within the region 
of the D4Z4 repeats and the molecular mechanism is still under 
study. continues on page 6 
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Limb Girdle Muscular Dystrophy 
Though listed under one title, Limb Girdle Muscular Dystrophy 
(LGMD) is in fact both clinically and genetically a heterogeneous 
group of conditions. Seven types (around 10% of all LGMD) 
are inherited in an autosomal dominant trait (named Type lA to 
Type lG) and are relatively mild, characterised by proximal 
muscle weakness, beginning in the hip girdle rep;ion and later 
progressing to the shoulder girdle region with dlStal muscle 
weakness occurring later (if at all). The autosomal recessive form 
of LGMD shows an even higher degree of heterogeneity than 
the autosomal dominant form (11 discrete types named Type 2A 
to Type 2K). Onset is usually in childhood, but can occur in 
maturity or middle age. The first evidence of the disease is usually 
the pelvic or, less frequently, the shoulder girdle, often with 
asymmetry of wasting when the upper limbs are fIrst involved. 
Spread from the lower to the upper limbs or vice versa occurs 
within 20 years. The rate of progression is variable, but usually 
severe disability with inability to walk sets in within 20 to 30 
years of onset. Age at death is variable with the largest number 
of patients dying in middle age. Though in most cases of LGMD 
the causative gene has been identified, identifying the underlying 
genetic defect in particular cases can be a daunting task. 
Other Dystrophies 
The Dystal Myopathies are rare forms of dystrophies associated 
with wasting and weakness of the distal muscles with minor 
involvement of other muscle groups. Clinically, the disorder 
follows a mild course though some individuals do suffer from 
severe mobility problems. At least four genetically distinct types 
have been identified so far. 
The OculopharyngeaI Muscular Dystrophy is an autosomal 
dominant disorder characterised by late adult onset, progressive 
ptosis and dysphagia. Other cranial and limb muscles can be 
involved as well. The gene associated with the disease is located 
on chromosome 14 and it is postulated that a triplet expansion 
in the PABPNl gene might be the causative agent. 
As the name implies, the relatively uncommon autosomal 
recessive Congenital Muscular Dystrophy, occurs at birth or 
early infancy. The child presents with hypotonia and generalised 
weakness with possible joint contractures. Individuals with the 
disorder tend to have severe muscle weakness, inability to walk 
and possible respiratory weakness. In most of the cases the disorder 
is caused by mutations in the merosin gene (chromosome 6) with 
some cases due to defIciency of its receptor (integrin a 7). 
Pathogenesis and Molecular Management 
Though muscle weakness is a ubiquitous feature in all cases 
of muscle dystrophy and even though most of the pathological 
molecular defects are known, the actual molecular pathogenesis 
is still not clear. The basic mechanism seems to indicate that the 
absence of a protein (or the presence of a mutated protein) in 
the DGC, and thus within the link between the extracellular 
matrix and intracellular actin molecules, causes a breakdown 
in the integrity of the muscle membrane that results in muscle 
weakness. But the actual mechanism by which this weakness 
occurs is still obscure. 
Apart from the use in counseling, molecular biological 
techniques are promising to produce important developments 
in the management of the disease. In addition to supportive 
measures of a good diet, reduction in weight, physiotherapy, 
controlled exercise and orthotic and surgical corrections, there 
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Figure 2: Dystrophin-Glycoprotein Complex (DGC) 
is the possibility of treating the disease by correcting the underlying 
defect. It is not surprising to note that as DMD is the most 
common muscular dystrophy and that the dystrophin gene has 
been fully characterized and studied, most of the treatment 
research has been concentrated on this disorder. The observation 
that the basic molecular pathology difference between DMD 
and BMD is that the Dystrophin gene is usually either severely 
truncated or absent in the former, whilst only shortened but 
partially functioning in the latter, has indicated a possible treatment 
strategy for DMD cases. There are at present 4 clinical trials (in 
various phases) that are targeting this approach and are attempting 
to revert a Duchene-type of mutation into a Becker's type 
(usually produced by what is known as exon skipping) that 
should in theory improve the prognosis. 
Arninoglycosides have previously been shown to suppress 
nonsense mutations, allowing translation of full-length proteins 
in vitro and in animal models. At the moment a number of 
clinical trials, both in the US as well as in Europe, are underway 
to determine both the safety and efficacy of Gentamycin IV 
injections in regenerating dystrophin proteins. Preliminary 
results have shown that such a treatment can be useful to at 
least a subset of patients with DMD that can be identifIed 
through the type of mutation present. The same approach has 
been taken through the use of anti-sense oligonucleotides. 
These are synthetic, short DNA sequences that are 
complimentary to the area of the DNA that contains the 
mutation. On binding to this area, the part of DNA is skipped 
during the translation process. A third clinical trial, that is 
entering into phase 2, is investigating the use of a small, oral 
molecule (called PTC124) to induce exon skipping. Preliminary 
results show that treatment with PTCl24 was associated with 
increases in muscle dystrophin expression. 
Other trials include the attempt to introduce the dystrophin 
gene, initially by direct injection but if successful, by systematic 
means. Other bio-pharmaceuticals that are at present undergoing 
clinical trials include the nutritional supplement coenzyme Q10 
in conjunction with steroid treatment, creatinine and L-glutarnine 
in steroid naive cases and the 'mast cell stabilizer' oxatomide 
drug. 
Another interesting approach would be to upregulate the 
dystrophin analogue, utrophin. This approach has been tested 
in genetically engineered mice with muscular dystrophy with 
the treated mice showing amelioration. Though this approach 
offers a novel and relatively safe treatment, the search for a safe 
compound that upregulates utrophin is still on. 
Muscular dystrophy is currently considered to be an incurable 
disease with an increased degree of morbidity and mortality. 
Through genetic studies and the use of bio-pharmaceuticals it 
is hoped that this dim future shall change into one that is brighter 
and which offers a hope to these patients. 8J 
